影像预测肝细胞癌预后:现状与未来展望
该综述指出肝细胞癌诊断已建立基于影像特征的标准化算法,但治疗决策缺乏个体化。综述从患者到影像特征层面概述肝细胞癌预后,重点讨论未来向更个体化治疗指导发展的方向。
要点
- 肝细胞癌诊断主要基于影像,病理分析用于影像特征不典型时。
- 标准化系统算法组合精确特征已成为肝细胞癌的诊断影像标志物。
- 未来创新方向可能包括预测和预后标志物以指导个体化治疗。
核心结论
- 肝细胞癌诊断已通过标准化影像算法取得创新,但治疗决策尚不精细且非个体化。
- 肝细胞癌生物学异质性源于分子、病理和患者层面复杂因素,影响治疗结局。
- 未来需从患者到影像特征层面发展预测和预后标志物以指导个体化治疗。
研究设计与样本
- 综述类文章,检索范围与纳入文献未在原文摘要中报告。
临床应用与阅片要点
- 日常阅片中应识别构成肝细胞癌诊断影像标志物的精确特征组合。
- 影像特征不典型时需结合病理分析以确诊肝细胞癌。
- 报告时应关注可能影响预后的影像特征,为个体化治疗提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The focus of hepatocellular carcinoma (HCC) research for many years has been on noninvasive diagnosis. Standardized systematic algorithms composed of combinations of precise features now serve as diagnostic imaging markers of HCC and constitute a major innovation for liver imaging. In clinical practice, the diagnosis of HCC is based primarily on imaging and secondarily on pathologic analysis if the imaging features are not specific. Whereas accurate diagnosis is essential, the next phase of innovation for HCC will likely encompass predictive and prognostic markers. HCC is a biologically heterogeneous malignancy because of complex molecular, pathologic, and patient-level factors that impact the outcomes of treatment. In recent years, there have been many advances in systemic therapy to augment and extend the existing large cache of local and regional options. However, the guideposts for treatment decisions are neither sophisticated nor individualized. This review provides an overview of prognosis in HCC from the patient to the imaging feature level with a focus on future directions toward more individualized treatment guidance.
引用
- Ronot, Chernyak, Burgoyne, et al. Imaging to Predict Prognosis in Hepatocellular Carcinoma: Current and Future Perspectives. Radiology. 2023. PMID: 37014244. doi:10.1148/radiol.221429
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。